ジェネリック抗レトロウイルス薬の使用とPEPFAR治療プログラムにおけるコスト削減
Charles B Holmes1, William Coggin, David Jamieson
1Office of the US Global AIDS Coordinator, US Department of State, Washington, DC 20522-2920, USA. holmescb@state.gov
JAMA
|July 20, 2010
まとめ
ジェネリック抗レトロウイルス薬 (ARV) の利用可能性は,PEPFARが支援するプログラムでのARV調達を大幅に増加させた. この変化は,実質的なコスト削減につながり,世界的な健康イニシアチブにおけるジェネリックARVの価値を実証しました.
科学分野:
- グローバル・ヘルス グローバル・ヘルス
- 薬学経済学 薬学経済学
- HIV/AIDSの治療について
背景:
- 抗レトロウイルス薬 (ARV) の高コストは,開発途上国における治療拡大を妨げています.
- 米国食品医薬品局 (FDA) は,ジェネリックARVの承認を加速し,米国大統領のエイズ救済緊急計画 (PEPFAR) のようなプログラムの可用性を高めました.
研究 の 目的:
- アフリカ,ギアナ,ハイチ,ベトナムのPEPFARが支援するプログラムにおけるジェネリックARVの採用を評価する.
- 時間の経過とともにARV利用と関連するコストの変化を分析する.
主な方法:
- PEPFARが支援する16カ国で2005年から2008年にかけてのARV調達に関する年次調査.
- 薬費の評価,ARVの種類,量,ジェネリック調達比率,コスト削減.
主要な成果:
- 一般的なARVの調達は2005年の14.8%から2008年の89.33%に劇的に増加しました.
- 推定コスト削減は,2008年までに3億2,300万ドルに達した.
- ARVの支出と調達量の大幅な増加が観察されました.
結論:
- 汎用ARVの利用可能性は,PEPFARプログラムにおけるARVの調達の増加と相関しています.
- 汎用ARVの使用の増加により,大幅なコスト削減が達成されました.
関連する概念動画
Retrovirus Life Cycles
43.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.0K
Retroviruses
12.1K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.1K
Pulmonary Tuberculosis V
1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Excretion
408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97


